- Home
- FUN vs ETNB Comparison
FUN vs ETNB Comparison
Compare FUN & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUN
- ETNB
- Stock Information
- Founded
- FUN 1983
- ETNB 2018
- Country
- FUN United States
- ETNB United States
- Employees
- FUN N/A
- ETNB N/A
- Industry
- FUN Services-Misc. Amusement & Recreation
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- FUN Consumer Discretionary
- ETNB Health Care
- Exchange
- FUN Nasdaq
- ETNB Nasdaq
- Market Cap
- FUN 2.2B
- ETNB 2.2B
- IPO Year
- FUN 1987
- ETNB 2019
- Fundamental
- Price
- FUN $22.98
- ETNB $14.84
- Analyst Decision
- FUN Buy
- ETNB Buy
- Analyst Count
- FUN 13
- ETNB 10
- Target Price
- FUN $36.08
- ETNB $22.31
- AVG Volume (30 Days)
- FUN 4.4M
- ETNB 5.9M
- Earning Date
- FUN 11-07-2025
- ETNB 11-07-2025
- Dividend Yield
- FUN 5.31%
- ETNB N/A
- EPS Growth
- FUN N/A
- ETNB N/A
- EPS
- FUN N/A
- ETNB N/A
- Revenue
- FUN $3,168,142,000.00
- ETNB N/A
- Revenue This Year
- FUN $17.13
- ETNB N/A
- Revenue Next Year
- FUN $5.96
- ETNB N/A
- P/E Ratio
- FUN N/A
- ETNB N/A
- Revenue Growth
- FUN 67.95
- ETNB N/A
- 52 Week Low
- FUN $20.00
- ETNB $4.16
- 52 Week High
- FUN $49.77
- ETNB $15.06
- Technical
- Relative Strength Index (RSI)
- FUN 48.23
- ETNB 76.55
- Support Level
- FUN $24.03
- ETNB $14.74
- Resistance Level
- FUN $27.37
- ETNB $14.85
- Average True Range (ATR)
- FUN 1.57
- ETNB 0.06
- MACD
- FUN 0.12
- ETNB -0.18
- Stochastic Oscillator
- FUN 40.43
- ETNB 76.92
About FUN Cedar Fair L.P.
Six Flags Entertainment Corp is North America's regional amusement resort operator with approximately 27 amusement parks, around 15 separately gated water parks, and nine resort properties across the U.S., Canada, and Mexico. It provides coasters, themed rides, thrilling water parks, resorts, and a portfolio of beloved intellectual properties such as Looney Tunes, DC Comics, and PEANUTS.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).